United Therapeutics Corporation http://www.alacrastore.com/company-snapshot/United_Therapeutics_Corporation-2100485 Friday, January 09, 2009 2:55:39 AM 2100485 United Therapeutics Corporation en AlacraStore RSS Builder 1.0 30 US - Eli Lilly & Co agreed to acquire an undisclosed minority stake in United Therapeutics Corp, a biotechnology company, for $### mil, in a privately negotiated transaction. The transaction was subject to regulatory approvals and other customary closing conditions.11/18/2008 2:22:58 PM53245791307C53245791307CEli Lilly & CoUnited Therapeutics CorpEli Lilly & CoUnited Therapeutics Corphttp://www.alacrastore.com/storecontent/Thomson_M%26A/Eli_Lilly_Co_acquires_a_minority_stake_in_United_Therapeutics_Corp-2027959020sdc/20279590202027959020Copyright © 2008, Thomson Financial, All Rights ReservedNew YorkDrugsUnited StatesPharmaceutical preparations2834INIndianaPublicLLY2048:Prepared animal feeds, except for dogs and cats2819:Industrial inorganic chemicals, nec2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations3841:Surgical and medical instruments and apparatus3844:X-Ray apparatus & tubes & other irradiation equip.5122:Drugs, drug proprietaries, and druggists' sundries8731:Commercial physical and biological research8741:Management services2048:Prepared animal feeds, except for dogs and cats2819:Industrial inorganic chemicals, nec2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations3841:Surgical and medical instruments and apparatus3844:X-Ray apparatus & tubes & other irradiation equip.5122:Drugs, drug proprietaries, and druggists' sundries8731:Commercial physical and biological research8741:Management servicesNasdaqBusiness ServicesUnited StatesCommercial physical and biological research8731MDMarylandPublicUTHR3547001Mnfr,whl pharmBiotech coCashCash OnlyCommon Stock524109002Nov 18 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.0000029.0000030.0000031.00000Eli Lilly & Co, headquarteredin Indianapolis, Indiana,manufactures and wholesalespharmaceuticals, medicalinstruments, diagnostic andanimal health products. Thepharmaceutical productsinclude: Neuroscience,Endocrine, Anti-infective,Cardiovascular agents,Oncology and Animal Health.The company specializes inresearch and development,production and marketing ofproducts for the treatment ofdiabetes worldwide, such asinsulin and insulin deliverydevices. The company providesresearch and developmentfacilities in nine countriesand conducts clinical trials.The company's patents includeZyprexa, Prozac, Permax,Darvon, Humulin, Evista,Humalog, Actos, Humatrope,Ceclor, Vancocin, Keflex,Nebcin , Lorabid, Gemzar,Tylan, Rumensin, Micotil,Surmax, Coban, ReoPro, Xigris,Dobutrex and Axid. The companywas founded on May 10, 1876.Eli Lilly & Co, headquartered in Indianapolis, Indiana,manufactures and wholesales pharmaceuticals, medicalinstruments, diagnostic and animal health products. Thepharmaceutical products include: Neuroscience, Endocrine,Anti-infective, Cardiovascular agents, Oncology and AnimalHealth. The company specializes in research and development,production and marketing of products for the treatment ofdiabetes worldwide, such as insulin and insulin deliverydevices. The company provides research and developmentfacilities in nine countries and conducts clinical trials.The company's patents include Zyprexa, Prozac, Permax,Darvon, Humulin, Evista, Humalog, Actos, Humatrope, Ceclor,Vancocin, Keflex, Nebcin , Lorabid, Gemzar, Tylan, Rumensin,Micotil, Surmax, Coban, ReoPro, Xigris, Dobutrex and Axid.The company was founded on May 10, 1876.Eli Lilly & Co, headquartered in Indianapolis, Indiana, manufactures and wholesales pharmaceuticals, medical instruments, diagnostic and animal health products. The pharmaceutical products include: Neuroscience, Endocrine, Anti-infective, Cardiovascular agents, Oncology and Animal Health. The company specializes in research and development, production and marketing of products for the treatment of diabetes worldwide, such as insulin and insulin delivery devices. The company provides research and development facilities in nine countries and conducts clinical trials. The company's patents include Zyprexa, Prozac, Permax, Darvon, Humulin, Evista, Humalog, Actos, Humatrope, Ceclor, Vancocin, Keflex, Nebcin , Lorabid, Gemzar, Tylan, Rumensin, Micotil, Surmax, Coban, ReoPro, Xigris, Dobutrex and Axid. The company was founded on May 10, 1876.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.00000United Therapeutics Corp,located in Silver Spring,Maryland, is a biotechnologycompany focused on thedevelopment andcommercialization of uniqueproducts for patients withchronic and life-threateningdiseases. It manufacturespharmaceuticals to treatcardiovascular, inflammatoryand infectious diseases. Itsproducts include Remodulin,inhaled and oral Treprostinil,Beraprost-MR, and inhaledTreprostinil with AERx essencefor the treatment of pulmonaryarterial hypertension. Thecompany was founded in 1996.United Therapeutics Corp, located in Silver Spring,Maryland, is a biotechnology company focused on thedevelopment and commercialization of unique products forpatients with chronic and life-threatening diseases. Itmanufactures pharmaceuticals to treat cardiovascular,inflammatory and infectious diseases. Its products includeRemodulin, inhaled and oral Treprostinil, Beraprost-MR, andinhaled Treprostinil with AERx essence for the treatment ofpulmonary arterial hypertension. The company was founded in1996.United Therapeutics Corp, located in Silver Spring, Maryland, is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening diseases. It manufactures pharmaceuticals to treat cardiovascular, inflammatory and infectious diseases. Its products include Remodulin, inhaled and oral Treprostinil, Beraprost-MR, and inhaled Treprostinil with AERx essence for the treatment of pulmonary arterial hypertension. The company was founded in 1996.0.000000.000000.0000023.23000NU.S. Dollar14 Nov 08Fri, 14 Nov 2008 00:00:00 ESTDate Announced: 11/14/2008Date Effective:Acq. Part. Int.Friendly0.000000.000000.000000.000000.000000.00000Price/Share0.00000150 U.S. Dollar150.000000.00000150 U.S. Dollar150.000000.000000.000000.000000.00000150.00000150 U.S. Dollar1.00000N101.798000.000000.000000.000000.000000.00000150.00000150.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.00000US - Eli Lilly & Co agreed toacquire an undisclosedminority stake in UnitedTherapeutics Corp, abiotechnology company, for$150 mil, in a privatelynegotiated transaction. Thetransaction was subject toregulatory approvals and othercustomary closing conditions.US - Eli Lilly & Co agreed to acquire an undisclosed minority stake in United Therapeutics Corp, a biotechnology company, for $150 mil, in a privately negotiated transaction. The transaction was subject to regulatory approvals and other customary closing conditions.US - Eli Lilly & Co agreed to acquire an undisclosed minority stake in United TherapeuticsCorp, a biotechnology company, for $150 mil, in a privately negotiated transaction. Thetransaction was subject to regulatory approvals and other customary closing conditions.US - Eli Lilly & Co agreed to acquire an undisclosed minority stake in United Therapeutics Corp, a biotechnology company, for $150 mil, in a privately negotiated transaction. The transaction wassubject to regulatory approvals and other customary closing conditions.US - Eli Lilly & Co agreed to acquire an undisclosed minority stake in United Therapeutics Corp, a biotechnology company, for $150 mil,in a privately negotiated transaction. The transaction was subject to regulatory approvals and other customary closing conditions.$ 150.000 - Merrill Lynch - Adv0.00000Merrill Lynch & Co Inc1.00000Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002824:Manmade organic fibers, except cellulosic2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research3547001New YorkUnited States2834IndianaPublicLLY2824:Manmade organic fibers, except cellulosic2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research524109002NasdaqUnited States8731MarylandPublicUTHR150.00000150.00000150.00000101.79800Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/B2033154ccbn/B2033154norm...Rather than having one of two pivotal trials for an oral PAH treatment successfully completed, which was Co.'s expectation, UTHR [has] filed NDA for an oral PAH treatment to announce, tadalafil via an in license agreement with Eli Lilly. www.streetevents.comContact Us ... 11/17/2008 3:06:00 PMUnited Therapeutics54.0000EditedUnited Therapeutics FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension SummaryUTHR9:00am ETBriefB2033154Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2033154ccbn/T2033154norm...Good morning. My name is Maranda, and I will be your conference operator today. At this time I would like to welcome everyone to the United Therapeutics Corporation conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. (Operator Instructions). Remarks today concerning United Therapeutics will include forward-looking statements which represents United Therapeutics' expectations and beliefs regarding future events based on current assumptions. United Therapeutics cautions include such statements, risks and uncertainties that may cause actual results to differ materially from which those forward-looking statements. Consequently all such forward-looking statements are qualified and cautionary language and risk factors set forth in United Therapeutics' periodic and other reports filed with the SEC. There can be no assumptions that our actual risks, events or developments referred in such forward-looking... 11/17/2008 2:06:00 PMUnited Therapeutics54.0000FinalUnited Therapeutics FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension TranscriptUTHR9:00am ETTranscriptT2033154Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B2006060ccbn/B2006060norm...FREEDOM-C study, already full enrolled, will unblind in just about another couple of weeks (Nov. ## plus or minus a couple of days or so, either side of that). ... 10/30/2008 2:07:00 PMUnited Therapeutics54.0000EditedUnited Therapeutics Q3 2008 Earnings Conference Call SummaryUTHR9:00am ETBriefB2006060Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2006060ccbn/T2006060norm...Good morning. My name is Whitney and I will be your conference operator today. At this time, I would like to welcome everyone to the United Therapeutics Corporation third-quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator Instructions) Remarks today concerning United Therapeutics will include forward-looking statements, which represents United Therapeutics expectations or beliefs regarding future events based on current assumptions. United Therapeutics cautions that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in United Therapeutics periodic and other reports filed with the SEC. There can be no assurance that the actual results, events, or... 10/30/2008 1:07:00 PMUnited Therapeutics54.0000FinalUnited Therapeutics Q3 2008 Earnings Conference Call TranscriptUTHR9:00am ETTranscriptT2006060Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-29070812newstex/PRN-0005-29070812xml SILVER SPRING, Md., Oct. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September ##, ####. Total revenues for...07000000070050000900000009015000040000000401600004016048040160180401600104016003040100000401000110/30/2008 8:24:17 AM180000001800400018008000PR Newswire USPRN-0005-29070812UNITED THERAPEUTICS CORPUnited Therapeutics CorporationMARTINE A ROTHBLATTUTHRNewsNewstexhttp://www.alacrastore.com/storecontent/bir/955380bir/955380normUnited Therapeutics Corp.United StatesManufacturing: Developer of pharmaceuticals to treat vascular disease.283432541217DHUTHR10/10/2008 6:14:42 AM955380Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/ccbn/T1909564ccbn/T1909564norm...Good morning. My name is Sim and I'll be your conference operator today. At this time, I'd like to welcome everyone to the United Therapeutics Corporation second quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. (OPERATOR INSTRUCTIONS) Remarks today concerning United Therapeutics will include forward-looking statements, which represent United Therapeutics' expectations or beliefs regarding future events based on current assumptions. United Therapeutics cautions that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in United Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments... 7/31/2008 3:10:00 PMUnited Therapeutics54.0000FinalUnited Therapeutics Q2 2008 Earnings Conference Call TranscriptUTHR9:00am ETTranscriptT1909564Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1909564ccbn/B1909564norm...These financial accomplishments reflect the decisions of hundreds of doctors and patients throughout US, Europe, and beyond to use Remodulin. ... 7/31/2008 11:06:00 AMUnited Therapeutics54.0000EditedUnited Therapeutics Q2 2008 Earnings Conference Call SummaryUTHR9:00am ETBriefB1909564Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1834893ccbn/T1834893norm...Good morning. My name is Janice, and I will be your conference operator today. At this time, I would like to welcome everyone to the United Therapeutics Corporation First Quarter Earnings Conference Call. (OPERATOR INSTRUCTIONS) Remarks today concerning United Therapeutics will include forward-looking statements, which represent United Therapeutics' expectations or beliefs regarding future events based on current assumptions. United Therapeutics cautions that such statements involve risks and uncertainties that may cause actual results to differ materially from those in forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in United Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. United Therapeutics assumes no obligation to update these forward-looking... 5/1/2008 2:06:00 PMUnited Therapeutics54.0000FinalQ1 2008 United Therapeutics Earnings Conference Call TranscriptUTHR9:00am ETTranscriptT1834893Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1834893ccbn/B1834893norm...UTHR reported #Q## revenue of $##m, net income of $##m, and earnings before non-cash charges of $##m. ... 5/1/2008 11:06:00 AMUnited Therapeutics54.0000EditedQ1 2008 United Therapeutics Earnings Conference Call SummaryUTHR9:00am ETBriefB1834893Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1764716ccbn/B1764716norm...This ##% operating leverage is likely to improve yet further in #### as Co. has reduced its basic spend against previous year revenues by #%. ... 2/19/2008 11:06:00 AMUnited Therapeutics54.0000EditedQ4 2007 United Therapeutics Earnings Conference Call SummaryUTHR9:00am ETBriefB1764716Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1764716ccbn/T1764716norm...Good morning. My name is Aldous, and I will be your conference operator today. At this time, I would like to welcome everyone to the United Therapeutics Corporation fourth-quarter earnings conference call. All lines have been placed on mute to prevent any background noise. (OPERATOR INSTRUCTIONS). Remarks today concerning United Therapeutics will include forward-looking statements, which represent United Therapeutics' expectations or beliefs regarding future events based on current assumptions. United Therapeutics cautions that such statements involve risks and uncertainties that may cause actual results to differ materially from those in forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in United Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be... 2/19/2008 11:06:00 AMUnited Therapeutics54.0000FinalQ4 2007 United Therapeutics Earnings Conference Call TranscriptUTHR9:00am ETTranscriptT1764716Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/27353srp/27353norm...Address:#### Spring Street, Silver Spring, Maryland ##### Incorporated:DelawareWeb Site: www.unither.comSIC Classification: Pharmaceutical Preparations (####) Business Description: United Therapeutics Corporation is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services. Indices:Russell ####, Russell ####, S&P ### IPO Date: ##-##-####... 2735391307C102UTHR10/6/2006 12:15:00 PM27353Credit & Investment ResearchSharkRepellent.net